ARQT: Arcutis Biotherapeutics, Inc. Stock

by  •  • Comments Off on ARQT: Arcutis Biotherapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,720.25
Enterprise Value ($M) 1,855.64
Book Value ($M) 157.54
Book Value / Share 1.33
Price / Book 10.92
NCAV ($M) 144.47
NCAV / Share 1.22
Price / NCAV 11.91

Profitability (mra)
Return on Invested Capital (ROIC) -0.38
Return on Assets (ROA) -0.41
Return on Equity (ROE) -1.58

Liquidity (mrq)
Quick Ratio 3.97
Current Ratio 4.15

Balance Sheet (mrq) ($M)
Current Assets 335.82
Assets 348.89
Liabilities 191.35
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 196.54
Operating Income -128.40
Net Income -140.04

Cash Flow Statement (mra) ($M)
Cash From Operations -112.16
Cash from Investing 28.82
Cash from Financing 66.20

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
11-14 13G/A Point72 Asset Management, L.P. 0.20 -94.92
11-13 13G/A Rubric Capital Management LP 9.38 65.05
11-08 13G/A BlackRock, Inc. 7.70 0.00
11-06 13G/A Morgan Stanley 3.40 -34.46
2024-03-06 13D/A Frazier Life Sciences VIII, L.P. 7.80 0.24
2024-03-06 13G/A Jennison Associates Llc 10.80 33.78
2024-02-14 13G/A Prudential Financial Inc 10.47 2.42
2024-02-13 13G Vanguard Group Inc 5.19
2024-02-13 13G/A Polar Capital Holdings Plc 6.67 -11.52
2024-02-13 13G/A Suvretta Capital Management, Llc 9.99 -0.60

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-02-25 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPO
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PU
2024-07-24 10-Q/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q/A Amendment No. 1 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 ☐ TRANSITION REPORT P

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 374,122 1,320,352 28.34
2025-03-06 431,723 1,849,867 23.34
2025-03-05 600,057 2,588,731 23.18
2025-03-04 672,599 2,560,416 26.27

(click for more detail)

Similar Companies
ANAB – AnaptysBio, Inc. ANNX – Annexon, Inc.
APLS – Apellis Pharmaceuticals, Inc. ARVN – Arvinas, Inc.
ARWR – Arrowhead Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io